This user has not added any information to their profile yet.
Lipid nanoparticles, Cubosomes, Nanomedicine, Vaccine delivery, mRNA delivery, Drug delivery, Tuberculosis, Antimicrobial resistance, Infectious diseases, Nanotechnology, Structural biophysics, Biomaterials, Controlled release, Pulmonary drug delivery, Inhaled therapeutics, Vaccine adjuvants, Diagnostics, Translational medicine.
I develop next-generation lipid nanocarrier technologies for vaccines, nucleic acid therapeutics, antimicrobial delivery, and diagnostics to address infectious diseases and antimicrobial resistance. My research integrates nanotechnology, structural biophysics, and microbiology to design and translate lipid nanoparticles and cubosomes from discovery through preclinical development and commercialisation. I welcome collaborations with academic, clinical, government, and industry partners to advance innovative solutions in nanomedicine, vaccine delivery, diagnostics, and advanced drug delivery systems.
Lipid nanoparticle formulation, cubosomes, mRNA and nucleic acid delivery, nanoparticle characterisation, SAXS, Cryo-TEM, DLS, zeta potential, fluorescence microscopy, cell culture, microbiology, antimicrobial susceptibility testing, molecular biology, nebulisation technologies, controlled drug delivery, vaccine formulation, structural biophysics, high-throughput formulation, assay development, translational research, intellectual property and commercialisation.
RMIT University
Massachusetts Institute of Technology (MIT)
Houston Methodist Research Institute
Australian Synchrotron
National Chemical Laboratory (India)
Clinical, academic and industry partners in vaccine development, infectious diseases, nanomedicine and translational research.
Antimicrobial Resistance (AMR)
Respiratory infectious diseases
Bacterial infections
Pulmonary drug delivery
Emerging infectious diseases
N/A
Recognised as a Victorian STEM Trailblazer (2025) and Finalist in the Australia Today International Women's Day Awards (2025).
Awarded the prestigious Endeavour Research Award, Veski Victoria Fellowship, and completed a Visiting Scientist Fellowship at MIT, USA.
Published 31 peer-reviewed publications, secured ~AUD $900K in competitive research funding, and is an inventor on 15 patents in translational nanomedicine and vaccine delivery.
Our laboratory is developing proprietary lipid nanoparticle and cubosome-based delivery technologies for vaccines, antimicrobial therapeutics, nucleic acid delivery, inhaled medicines, and diagnostic applications. We welcome discussions with industry partners interested in licensing, co-development, and commercial translation of innovative platform technologies.
We are interested in partnering with biotechnology, pharmaceutical, diagnostics, medical device, and healthcare companies through collaborative research, grant-funded projects, contract research, technology validation, licensing, and commercialisation of innovative nanomedicine and diagnostic platforms.
Our research bridges fundamental nanoscience with real-world healthcare solutions. By combining expertise in lipid nanotechnology, infectious disease biology, and translational medicine, we work closely with academic and industry partners to accelerate the development of innovative vaccines, antimicrobial therapeutics, diagnostics, and advanced drug delivery technologies that address global health challenges
- Aptamer-Loaded Cubosome Lipid Nanoparticles for the Treatment of Tuberculosis.
- Optimizing Lutein Formulations for Targeted Ocular Drug Delivery: In Vitro and In Vivo Insights.
- Overcoming Therapeutic Challenges of Antibiotic Delivery with Cubosome Lipid Nanocarriers.
- Prospective Subunit Nanovaccine against Mycobacterium tuberculosis Infection─Cubosome Lipid Nanocarriers of Cord Factor, Trehalose 6,6' Dimycolate.
- Progesterone-Cationic Lipid Conjugate-Based Self-Aggregates for Cancer Cell-Selective Uptake through Macropinocytosis and the Antitumour Effect.
- Cubosome Lipid Nanocarriers As a Drug Delivery Vehicle for Intracellular Mycobacterium tuberculosis Infections.
- Detection of a target protein (GroEl2) in Mycobacterium tuberculosis using a derivative of 1,2,4-triazolethiols.
- Uptake Dynamics of Cubosome Nanocarriers at Bacterial Surfaces and the Routes for Cargo Internalization.
- Cuboplex-Mediated Nonviral Delivery of Functional siRNA to Chinese Hamster Ovary (CHO) Cells.
- Tuning Nanostructured Lyotropic Liquid Crystalline Mesophases in Lipid Nanoparticles with Protic Ionic Liquids.
